- Home
- LU vs HELP Comparison
LU vs HELP Comparison
Compare LU & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | HELP |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 862.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LU | HELP |
|---|---|---|
| Price | $0.84 | $10.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $2.50 | ★ $40.33 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $3.76 |
| 52 Week High | $3.44 | $15.15 |
Technical Indicators
Market Signals| Indicator | LU | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 28.48 | 42.94 |
| Support Level | N/A | $9.97 |
| Resistance Level | $1.42 | $14.75 |
| Average True Range (ATR) | 0.05 | 0.90 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 3.19 | 22.83 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.